The European Medical Journal is proud to announce the upcoming launch of its new iPad app, soon to be available free-of-charge to download from the App Store.

Due for release on 8th August 2013, the app will allow doctors to easily navigate any of the journals, enabling them to ‘favourite’ specific articles dedicated to their particular speciality, easily access recently viewed manuscripts and  download all content at their own convenience. Previews of future editions, accompanied by release dates, will also be available.

European Medical Journal Director, Spencer Gore, said: “At the European Medical Journal, we are working incredibly hard to make our content available to even the busiest of doctors".

“The new app is just one of the many ways that they can now keep in touch with the latest developments, and gives us a platform, moving forward, to help with the unmet educational needs of the physician. This is the latest in a series of exciting new ventures we are currently working on.”

With a new website design soon to follow, the app – developed in partnership with Tip Medical Communications, Inc. – is yet another step in a long line of rapid growth recently enjoyed by the publication, after the journal unveiled a revamped house design earlier this month, along with a daily newsletter due to launch later this month. Ira Flood, Managing Director at Tip Medical Communications, Inc. commented: “TIP is very excited about the opportunity to partner with EMJ in developing this unique application and helping to reach HCP’s with a mobile experience.”

For editorial queries, please contact Kelly-Ann Lazarus, Editor at European Medical Journal, on +44 (0)1245 334452 or at: kelly-ann.lazarus@emjreviews.com
To discuss commercial opportunities, please contact Spencer Gore, Director at European Medical Journal, on +44 (0) 1245 334460 or at: spencer@emjreviews.com

END

NORGINE AND ALFA WASSERMANN SpA PARTNER WITH THE EUROPEAN MEDICAL JOURNAL TO ISSUE A LEADING EASL CONGRESS REVIEW REPORT ON HEPATIC ENCEPHALOPATHY (HE)

Professor D. Häussinger Clinic for Gastroenterology, Hepatology and Infectious Diseases Liver Center Düsseldorf, Heinrich Heine University Düsseldorf discusses a new pathophysiological concept for HE, new diagnostic methods, new aspects of sociomedical relevance and new treatment options available to treat HE.

Dr Peter Jepsen, Departments of Hepatology and Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark examines HE epidemiology and how HE can affect a patient’s life and concludes that HE is a continuum; in its overt form it is associated with a very high mortality with an expected survival time of approximately 6 months and with a high incidence post cirrhosis diagnosis; a better understanding of risk factors for HE development and recurrence is important.

Rajiv Jalan, UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK reviews strategies to improve the diagnosis and management of hepatic encephalopathy. There is a new focus on HE with more treatment options coming and better understanding pathogenesis that will enable improved classification.

 Professor Fred Poordad MD, Professor of Medicine, VP, Academic and Clinical Affairs, The Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, discusses prevention of recurrence of overt hepatic encephalopathy and highlights that there are limited therapeutic options for HE, but the new broad spectrum, non-absorbed antibiotic therapy, rifaximin α which is well tolerated, is effective and suitable for long term use. He also mentions that new therapeutic options will focus on enhancing survival in advanced liver disease.

EASLis the leading liver association in Europe. It attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policy.

Norgine is committed to improving the lives of patients with hepatic encephalopathy and has provided an educational grant for the development of a medical educational programme ‘New Insights into HE’. For more information, visit http://www.hepaticencephalopathy.info.

Ends